Intersect ENT, Inc. (XENT): Price and Financial Metrics


Intersect ENT, Inc. (XENT): $27.14

0.01 (+0.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

XENT POWR Grades


  • Quality is the dimension where XENT ranks best; there it ranks ahead of 64.75% of US stocks.
  • The strongest trend for XENT is in Quality, which has been heading up over the past 48 weeks.
  • XENT ranks lowest in Stability; there it ranks in the 12th percentile.

XENT Stock Summary

  • Intersect ENT Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 79.83% of US listed stocks.
  • XENT's went public 7.18 years ago, making it older than 25.85% of listed US stocks we're tracking.
  • XENT's price/sales ratio is 8.81; that's higher than the P/S ratio of 80.22% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Intersect ENT Inc, a group of peers worth examining would be BIOL, LMND, ATRC, EKSO, and XXII.
  • XENT's SEC filings can be seen here. And to visit Intersect ENT Inc's official web site, go to www.intersectent.com.

XENT Valuation Summary

  • XENT's price/sales ratio is 8.8; this is 22.47% lower than that of the median Healthcare stock.
  • XENT's price/earnings ratio has moved up 3.3 over the prior 86 months.
  • XENT's price/sales ratio has moved down 1.8 over the prior 86 months.

Below are key valuation metrics over time for XENT.

Stock Date P/S P/B P/E EV/EBIT
XENT 2021-08-31 8.8 21.8 -13.3 -14.7
XENT 2021-08-30 8.8 21.8 -13.3 -14.7
XENT 2021-08-27 9.0 22.1 -13.5 -14.9
XENT 2021-08-26 9.0 22.1 -13.5 -14.9
XENT 2021-08-25 9.0 22.1 -13.5 -14.9
XENT 2021-08-24 9.0 22.1 -13.5 -14.9

XENT Growth Metrics

  • Its 4 year revenue growth rate is now at 57.59%.
  • Its 5 year net cashflow from operations growth rate is now at -47.39%.
  • Its 2 year price growth rate is now at -66.72%.
XENT's revenue has moved up $46,398,000 over the prior 70 months.

The table below shows XENT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 102.625 -45.884 -68.294
2021-03-31 85.056 -46.51 -74.817
2020-12-31 80.554 -35.694 -72.319
2020-09-30 84.08 -32.347 -60.079
2020-06-30 85.416 -31.581 -61.462
2020-03-31 102.295 -26.315 -49.722

XENT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XENT has a Quality Grade of C, ranking ahead of 64.75% of graded US stocks.
  • XENT's asset turnover comes in at 0.506 -- ranking 92nd of 183 Medical Equipment stocks.
  • NUVA, IART, and NVRO are the stocks whose asset turnover ratios are most correlated with XENT.

The table below shows XENT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.506 0.675 -0.423
2021-03-31 0.432 0.620 -0.416
2020-12-31 0.452 0.624 -0.441
2020-09-30 0.531 0.657 -0.399
2020-06-30 0.578 0.697 -0.468
2020-03-31 0.746 0.770 -0.470

XENT Price Target

For more insight on analysts targets of XENT, see our XENT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.21 Average Broker Recommendation 2.06 (Hold)

XENT Stock Price Chart Interactive Chart >

Price chart for XENT

XENT Price/Volume Stats

Current price $27.14 52-week high $28.17
Prev. close $27.13 52-week low $14.68
Day low $27.08 Volume 206,600
Day high $27.22 Avg. volume 411,266
50-day MA $25.70 Dividend yield N/A
200-day MA $22.09 Market Cap 904.17M

Intersect ENT, Inc. (XENT) Company Bio


Intersect ENT provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company was founded in 2003 and is based in Menlo Park, California.


XENT Latest News Stream


Event/Time News Detail
Loading, please wait...

XENT Latest Social Stream


Loading social stream, please wait...

View Full XENT Social Stream

Latest XENT News From Around the Web

Below are the latest news stories about Intersect ENT Inc that investors may wish to consider to help them evaluate XENT as an investment opportunity.

SHAREHOLDER ALERT: Monteverde & Associates PC Continues to Investigate the Following Merger

NEW YORK, NY / ACCESSWIRE / September 23, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Intersect ENT, Inc. (NASDAQ:XENT) relating to its proposed acquisition by Medtronic plc.

Yahoo | September 23, 2021

Lifshitz Law Firm, P.C. Announces Investigation of CLDB, XENT, SBKK, and VEI

NEW YORK, NY / ACCESSWIRE / September 21, 2021 /Cortland Bancorp (NASDAQ:CLDB) Lifshitz Law Firm, P. announces investigation into possible breach of fiduciary duties in connection with the sale of CLDB to Farmers National Banc Corp.

Yahoo | September 21, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XENT, INOV, SAFM, HOMB; Shareholders are Encouraged to Contact the Firm

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Intersect ENT, Inc. (NASDAQ: XENT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Medtronic plc for $28.25 per share. If you are an Intersect ENT shareholder, click here to learn more about your rights and options. Inovalon Holdings, Inc. (NASDAQ: INOV) concerning potent

Yahoo | September 20, 2021

SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

NEW YORK, NY / ACCESSWIRE / September 17, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Intersect ENT, Inc. (NASDAQ:XENT)relating to its proposed acquisition by Medtronic plc.

Yahoo | September 18, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SIC, XENT, INOV, SAFM; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | September 17, 2021

Read More 'XENT' Stories Here

XENT Price Returns

1-mo -1.74%
3-mo 64.58%
6-mo 40.48%
1-year 67.22%
3-year -4.60%
5-year 69.31%
YTD 18.52%
2020 -8.03%
2019 -11.64%
2018 -13.02%
2017 167.77%
2016 -46.22%

Continue Researching XENT

Want to see what other sources are saying about Intersect ENT Inc's financials and stock price? Try the links below:

Intersect ENT Inc (XENT) Stock Price | Nasdaq
Intersect ENT Inc (XENT) Stock Quote, History and News - Yahoo Finance
Intersect ENT Inc (XENT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.3788 seconds.